OverviewSuggest Edit

Kineta is a biotechnology company that is engaged in the discovery and development of antiviral therapies and immune-modulating drugs for the treatment of RNA viruses that include hepatitis C, influenza, west nile virus, and common cold. It offers ShK Analogs for treatment of multiple sclerosis and autoimmune diseases; and RIG-I Pathway, a molecular on/off switch that triggers the human body's immune defenses against virus infection.
TypePrivate
Founded2008
HQSeattle, WA, US
Websitekinetabio.com

Latest Updates

Employees (est.) (Apr 2021)32(+4%)
Cybersecurity ratingCMore

Key People/Management at Kineta

Shawn Iadonato

Shawn Iadonato

Director & CEO
Craig W. Philips

Craig W. Philips

President
Eric Tarcha

Eric Tarcha

EVP, Research & Development
Jacques Bouchy

Jacques Bouchy

SVP, Business Development & Corporate Communications
Pauline Kenny

Pauline Kenny

General Counsel
Molly Dorr

Molly Dorr

Head of Human Resources & Operations
Show more

Kineta Office Locations

Kineta has an office in Seattle
Seattle, WA, US (HQ)
219 Terry Ave N #300
Show all (1)

Kineta Financials and Metrics

Summary Metrics

Founding Date

2008

Kineta total Funding

$42.2 m

Kineta latest funding size

$1.8 m

Time since last funding

2 years ago

Kineta investors

Kineta's latest funding round in August 2019 was reported to be $1.8 m. In total, Kineta has raised $42.2 m
Show all financial metrics

Kineta Cybersecurity Score

Cybersecurity ratingPremium dataset

C

74/100

SecurityScorecard logo

Kineta Online and Social Media Presence

Embed Graph

Kineta News and Updates

Kineta Presents New Preclinical Data on its Lead VISTA Antagonist Antibody at the AACR Annual Meeting 2021

SEATTLE, April 12, 2021 /PRNewswire/ -- Kineta, Inc., a clinical stage biotechnology company focused on the development of novel immunotherapies in oncology, announced today the presentation of new preclinical data on its VISTA antagonist antibody at the American Association for Cancer...

Kineta Presents Clinical Study Results of LHF-535 at the International Conference on Antiviral Research (ICAR)

SEATTLE, March 25, 2021 /PRNewswire/ -- Kineta, Inc., a clinical stage biotechnology company focused on the development of novel immunotherapies, announced today the presentation of new clinical data on LHF-535 at the International Conference on Antiviral Research (ICAR) Virtual...

Kineta Presenting at Multiple Investor Conferences in March 2021

SEATTLE, March 3, 2021 /PRNewswire/ -- Kineta, Inc., a clinical stage biotechnology company focused on the development of novel immunotherapies in oncology and neuroscience announced today that Kineta will be presenting at multiple virtual investor events in March 2021. Shawn Iadonato,...

Kineta to Extend Research Collaboration with Genentech to Develop a Novel Non-Opioid

SEATTLE, Oct. 8, 2020 /PRNewswire/ -- Kineta Chronic Pain, LLC, a subsidiary of Kineta, Inc. announced today that the company will extend and expand its research collaboration with Genentech, a member of the Roche Group. With the extension, Kineta will continue development of α9/α10...

Kineta Invited to Participate at the Cowen and Company 40th Annual Health Care Conference

SEATTLE, Feb. 27, 2020 /PRNewswire/ -- Kineta, Inc., a clinical stage biotechnology company focused on the development of novel immunotherapies in oncology, neuroscience and biodefense announced today that Kineta's management team has been invited to participate at Cowen and Company 40th...

Kineta Invited to Participate at the BIO CEO & Investor Conference

SEATTLE, Feb. 5, 2020 /PRNewswire/ -- Kineta, Inc., a clinical stage biotechnology company focused on the development of novel immunotherapies in oncology, neuroscience and biodefense announced today that Kineta's management team has been invited to participate at the BIO CEO & Investor...
Show more

Kineta Blogs

Kineta Announces First Participant Dosed in Phase 1 Clinical Trial of KCP506, A Novel Non-Opioid for the Treatment of Chronic Pain

Kineta Announces First Participant Dosed in Phase 1 Clinical Trial of KCP506, A Novel Non-Opioid for the  Treatment of Chronic Pain Seattle, WA — (December 15, 2020) Kineta Inc, through its subsidiary Kineta Chronic Pain LLC, announced today that the first participant has been successfully dosed in …

Kineta Presents New Preclinical Data at ESMO Virtual Congress 2020 on its VISTA Antagonist Antibodies

Kineta Presents New Preclinical Data at ESMO Virtual Congress 2020 on its VISTA Antagonist Antibodies Seattle, WA — (December 9, 2020) Kineta, Inc., a clinical stage biotechnology company focused on the development of novel immunotherapies in oncology and neuroscience, announced today the presentati…

Kineta Presents New Preclinical Data at the 2020 SITC Annual Meeting on its VISTA Antagonist Antibodies

Kineta Presents New Preclinical Data at the 2020 SITC Annual Meeting on its VISTA Antagonist Antibodies Preclinical data demonstrates that VISTA is a novel target checkpoint against immunosuppressive myeloid cells Seattle, WA — (November 12, 2020) Kineta, Inc., a clinical stage biotechnology company…

Kineta Presents New Preclinical Data on its VISTA Antagonist Antibodies at the American Association for Cancer Research Virtual Special Conference on Tumor Immunology and Immunotherapy

Kineta Presents New Preclinical Data on its VISTA Antagonist Antibodies at the American Association for Cancer Research (AACR) Virtual Special Conference on  Tumor Immunology and Immunotherapy Seattle, WA — (October 20, 2020) Kineta, Inc., a clinical stage biotechnology company focused on the develo…

Kineta to Participate in BIO Investor Forum Digital

Kineta to Participate in BIO Investor Forum Digital Seattle, WA — (October 2, 2020) Kineta, Inc., a clinical stage biotechnology company focused on the development of novel immunotherapies in oncology, neuroscience and biodefense announced today that Kineta will be participating in the BIO Investor …

Kineta to Present at September 2020 Virtual Investor Conferences

Kineta to Present at September 2020 Virtual Investor Conferences Seattle, WA — (September 11, 2020) Kineta, Inc., a clinical stage biotechnology company focused on the development of novel immunotherapies in oncology, neuroscience and biodefense announced today that Kineta will be presenting at mult…
Show more

Kineta Frequently Asked Questions

  • When was Kineta founded?

    Kineta was founded in 2008.

  • Who are Kineta key executives?

    Kineta's key executives are Shawn Iadonato, Craig W. Philips and Eric Tarcha.

  • How many employees does Kineta have?

    Kineta has 32 employees.

  • Who are Kineta competitors?

    Competitors of Kineta include Sigilon, Rubius Therapeutics and Atara Biotherapeutics.

  • Where is Kineta headquarters?

    Kineta headquarters is located at 219 Terry Ave N #300, Seattle.

  • Where are Kineta offices?

    Kineta has an office in Seattle.

  • How many offices does Kineta have?

    Kineta has 1 office.